Exact Sciences Stock Forecast, Price & News

Exact Sciences' stock was trading at $57.82 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EXAS stock has increased by 113.1% and is now trading at $123.23.
View which stocks have been most impacted by COVID-19.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Exact Sciences or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Exact Sciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Exact Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Exact Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, February 9th 2021.
View our earnings forecast for Exact Sciences.

Exact Sciences Co. (NASDAQ:EXAS) announced its quarterly earnings data on Sunday, November, 1st. The medical research company reported ($1.46) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.51) by $0.95. The medical research company earned $408.40 million during the quarter, compared to analyst estimates of $337.43 million. Exact Sciences had a negative return on equity of 11.71% and a negative net margin of 25.27%. The firm's revenue for the quarter was up 86.7% on a year-over-year basis. During the same quarter last year, the business posted ($0.31) earnings per share.
View Exact Sciences' earnings history.

15 brokers have issued 1-year price targets for Exact Sciences' shares. Their forecasts range from $70.00 to $160.00. On average, they expect Exact Sciences' share price to reach $127.40 in the next twelve months. This suggests a possible upside of 3.4% from the stock's current price.
View analysts' price targets for Exact Sciences.

Some companies that are related to Exact Sciences include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seagen (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Novavax (NVAX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), salesforce.com (CRM), PayPal (PYPL), Square (SQ), Advanced Micro Devices (AMD), The Walt Disney (DIS) and AbbVie (ABBV).

Exact Sciences trades on the NASDAQ under the ticker symbol "EXAS."

Exact Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include William Blair Investment Management LLC (1.45%), Nuveen Asset Management LLC (0.75%), Natixis (0.74%), First Trust Advisors LP (0.62%), Factory Mutual Insurance Co. (0.51%) and Swiss National Bank (0.39%). Company insiders that own Exact Sciences stock include D Scott Coward, G Bradley Cole, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Mark Stenhouse, Scott C Johnson and Torsten Hoof.
View institutional ownership trends for Exact Sciences.

EXAS stock was sold by a variety of institutional investors in the last quarter, including Toronto Dominion Bank, Durable Capital Partners LP, Handelsbanken Fonder AB, Paloma Partners Management Co, ArrowMark Colorado Holdings LLC, Pictet & Cie Europe SA, New York State Common Retirement Fund, and Artemis Investment Management LLP. Company insiders that have sold Exact Sciences company stock in the last year include G Bradley Cole, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Mark Stenhouse, and Torsten Hoof.
View insider buying and selling activity for Exact Sciences.

EXAS stock was purchased by a variety of institutional investors in the last quarter, including Natixis, ARK Investment Management LLC, William Blair Investment Management LLC, Peregrine Capital Management LLC, Worldquant Millennium Advisors LLC, Wasatch Advisors Inc., Nikko Asset Management Americas Inc., and Factory Mutual Insurance Co..
View insider buying and selling activity for Exact Sciences.

Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of EXAS stock can currently be purchased for approximately $123.23.

Exact Sciences has a market capitalization of $18.54 billion and generates $876.29 million in revenue each year. The medical research company earns $-83,990,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis. Exact Sciences employs 4,110 workers across the globe.

The official website for Exact Sciences is www.exactsciences.com.

Exact Sciences' mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The medical research company can be reached via phone at 608-535-8815 or via email at [email protected]